Insulin-like Growth Factor I Gene Expression in the Uterus Is Stimulated by Tamoxifen and Inhibited by the Pure Antiestrogen ICI 182780

Cancer Research

Volumn 53, Issue 23, 1993, Pages 5585-5588

  Huynh, Hung T ^a   Pollak, Michael ^b  

^a Lady Davis Research Institute of the Sir Mortimer B Davis Jewish General Hospital ^*

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; SOMATOMEDIN C; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; HORMONE ACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS REGULATION; RAT; UTERUS GROWTH; UTERUS WEIGHT;

ANIMAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; INSULIN-LIKE GROWTH FACTOR I; ORGAN WEIGHT; RATS; RATS, SPRAGUE-DAWLEY; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; UTERUS;

EID: 0027432309     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Murphy, L. J. Murphy, L. C. and Friesen, H. G. Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol. Endocrinol. 1: 445-450, 1987.
2. Murphy, L. and Ghahary, A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr. Rev. 11: 443-453, 1990.
3. Lerner, L. and Jordan, V. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res. 50: 4177-4189, 1990.
4. Fornander, T. Rutqvist, L. E. and Wilking, N. Effects of tamoxifen on the female genital tract. Ann. NY Acad. Sci. 622: 469-476, 1991.
5. Andersson, M. Storm, H. H. and Mouridser, H. T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl. Cancer Inst, 83: 1013-1017, 1991.
6. Fornander, T. Cedermark, B., Mattsson, S. Skoog, L., Theve, T. Askergren, J., Rutqvist, L.E. Glas, U. Silfversward, C., Somell, A. Wilking, N. and Hjalmar, M.L. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 2: 117-120, 1989.
7. Magriples, U. Naftolin, F, Schwartz, R E, and Carcangiu, M. L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol, 11: 485-490, 1993.
8. Tannenbaum, G. S. Gurd, W. Lapointe, M, and Pollak, M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130: 3395-3401, 1992.
9. Malaab, S. A. Pollak, M. N. and Goodyer, C. G. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer, 28A: 788-793, 1992.
10. Huynh, H. T. Tetenes, E. Wallace, L, and Pollak, M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res, 53: 1727-1730, 1993.
11. Pollak, M. N. Costantino, J. Polychronakos, C, Blauer, S. Guyda, H, Redmond, C. Fisher, B, and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst, 82: 1693-1697, 1990.
12. Friedel, A. Jordan, V, and Pollak, M. Reduction in serum IGF-I levels following commencement of tamoxifen therapy. Eur. J. Cancer, 29A: 1368-72, 1993.
13. Pollak, M. Powles, T. J. Baum, M. and Sacks, N. Tamoxifen used as a chemo-jpreventative agent lowers serum IGF-I levels. Proc. Am. Assoc. Cancer Res, 34: Abstract 1518, 1993.
14. Wakeling, A. E. Dukes, M. and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res, 57: 3867-3873, 1991.
15. Jordan, V. Effect of tamoxifen on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12: 419-424, 1976.
16. Murphy, L. J. Bell, G. I. Duckworth, M. L. and Friesen, H. G. Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology, 121: 684-691, 1987.
17. Adams, M. D. Kelley, J. M. Gocayne, J. D. Dubnick, M. Polymeroppulos, M. H. Xiao, H. Merril, C. R. Wu, A. Olde, B, Moreno, R. F. Kerlavage, A. R. McCombie, W. R. and Venter, J. C. Complementary DNA sequencing: expressed sequence tags and human genome project. Science Washington DC), 252: 1651-1656, 1991.
18. Ignar-Trowbridge, D. M. Nelson, K. G. Bidwell, M. C. Curtis, S. W. Washburn, T. F. McLachlan, J. A. and Karach, K. S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA, 89: 4658-4662, 1991.
19. Pollak, M. N. Huynh, H. T. and Lefebvre, S. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res. Treat, 22: 91-100, 1992.
20. Pollak, M. Effects of adjuvant tamoxifen therapy on growth hormone and IGF-I physiology. In: S. Salmon (ed.), Adjuvant Therapy of Cancer, Vol. 7, pp. 43-54. Philadelphia: J. B. Lippincott Co, 1993.
21. Swenerton, K. D. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat. Rep, 64: 805-811, 1980.
22. Jordan, V. C. Gottardis, M. M. and Satyaswaroop, P. G. Tamoxifen-stimulated growth of human endometrial carcinoma. Ann. NY Acad. Sci, 622: 439-446, 1991.
23. Dilts, P. V. Hopkins, M. P. Chang, A. E. and Cody, R. L. Rapid growth of leiomyoma in patient receiving tamoxifen. Am. J. Obstet. Gynecol, 166: 167-168, 1992.